drugset / Trial / NCT03192969
A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
RandomizedParallel-groupDouble-blindTreatment
Summary
To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.
Timeline
- Start
- 2017-07-15
- Primary completion
- 2020-06-07
- Completion
- 2021-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 125 mg | Subcutaneous |
| Subject | Prednisolone | Other / unclassified | — | Oral |
| Subject | Prednisone | Other / unclassified | — | Oral |